Loading... (0%)
About liver disease

Press releases

GENFIT: Official Launch of the NASH Pediatric Program, following PIP and PSP Agreement by EMA and FDA
Published on: 01/23/2018
GENFIT: Half-Year Report of Liquidity Contract with CIC
Published on: 01/12/2018
GENFIT: Announces its Financial Calendar for 2018
Published on: 01/12/2018
GENFIT: Additional Resources Allocated to the Liquidity Agreement
Published on: 12/08/2017
GENFIT: Contributing Significantly to the European LITMUS Initiative on NASH Biomarkers
Published on: 11/27/2017
GENFIT: Positive Outcome from the 18-month Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor
Published on: 11/22/2017
GENFIT completes a €180 million offering of bonds convertible into new shares and/or exchangeable for existing shares (“OCEANEs”) due 2022
Published on: 10/17/2017
GENFIT announces the success of its offering of bonds convertible into new shares and/or exchangeable for existing shares (“OCEANEs”) due 2022 for an amount of €180 million
Published on: 10/11/2017
GENFIT launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (“OCEANEs”) due 2022 for an amount of approximately €150 million
Published on: 10/11/2017
GENFIT: Third quarter 2017 financial information
Published on: 10/11/2017
News
  • Shareholders Letter
    N°8, October 2017
Corporate information
  • Analyst/Investor presentation
    October 2017
Financial information
Contact

If you want to contact our Press Relations team, please do not hesitate to send us a message.

Contact us

 
d03d993809f5a01ddf5c82e60baf6efbdddddddddddddddddddd